Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
40.66
+1.52 (3.88%)
At close: Dec 20, 2024, 4:00 PM
40.90
+0.24 (0.59%)
After-hours: Dec 20, 2024, 7:54 PM EST
Kymera Therapeutics Employees
Kymera Therapeutics had 187 employees as of December 31, 2023. The number of employees increased by 20 or 11.98% compared to the previous year.
Employees
187
Change (1Y)
20
Growth (1Y)
11.98%
Revenue / Employee
$468,251
Profits / Employee
-$895,583
Market Cap
2.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 187 | 20 | 11.98% |
Dec 31, 2022 | 167 | 26 | 18.44% |
Dec 31, 2021 | 141 | 66 | 88.00% |
Dec 31, 2020 | 75 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Surgery Partners | 13,500 |
Concentra Group Holdings Parent | 9,020 |
Patterson Companies | 7,600 |
Neogen | 2,917 |
LivaNova | 2,900 |
HUTCHMED (China) | 1,988 |
SpringWorks Therapeutics | 305 |
Catalyst Pharmaceuticals | 167 |
KYMR News
- 15 days ago - Kymera: Protein Degradation Could Drive Dupixent-Like Value - Seeking Alpha
- 25 days ago - Kymera Therapeutics to Participate in Upcoming December Investor Conferences - GlobeNewsWire
- 6 weeks ago - Kymera Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 6 weeks ago - Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - GlobeNewsWire
- 2 months ago - Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - GlobeNewsWire